You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美藥企ITCI暴漲逾193% 精神分裂症新藥獲FDA批准
格隆匯 12-24 09:01
格隆匯12月24日丨美國藥企Intra-Cellular Therapies(ITCI)宣佈,旗下治療成人精神分裂症的新藥Caplyta已經獲得FDA批准,將於明年一季度上市。受此消息影響,ITCI週一收漲193.49%,報36.51美元,最新總市值20.18億美元。ITCI此次獲批的新藥Caplyta,治療原理是對三種神經傳導機制:血清素、多巴胺和穀氨酸產生影響來改善各種心理疾病的症狀。在此次的審批中,FDA嚴厲地指出,此種藥物不能用於失智症相關的精神疾病治療。根據ITCI的安排,Caplyta的定價和上市將會在2020年一季度完成。 注:可關注港A股市場相關概念的上市公司,如:石藥集團、綠葉製藥、恆瑞醫藥、康弘藥業、華海藥業和恩華藥業等。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account